Company launches first Prime Site in Latin America RESEARCH TRIANGLE PARK, N.C. - Thursday, April 16th 2015 [ME NewsWire]
(BUSINESS WIRE) -- Quintiles today announced a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program. Hospital Italiano is Quintiles’ first Prime Site in Latin America, complementing the company’s robust network of investigative sites across the globe.
A Prime Site is a large clinical institution selected by Quintiles to work together and enhance the institution’s infrastructure for conducting clinical trials in order to accelerate the development of new and more effective medicines. Quintiles and a Prime Site work together to create a more efficient clinical trial process by recruiting, enrolling and retaining more patients through the course of a clinical trial. The new agreement with Hospital Italiano is designed to involve more patients in clinical trials than has previously been possible in one location in Latin America, increasing patient access to medications. Ultimately, this agreement will help accelerate the collection of critical data about the safety and efficacy of investigational therapies.
“According to the Tufts Center for the Study of Drug Development, timelines are typically extended to nearly double their original duration to meet desired patient enrolment levels across all therapeutic areas — delays that can increase costs, deplete resources and prolong the time it takes for drugs to get to patients in need,” said Jeanne Hecht, senior vice president of Site & Patient Networks at Quintiles. “Quintiles recognizes these challenges and is dedicated to working together differently across the healthcare system to transform drug development and achieve better patient outcomes.”
The new Prime Site at Hospital Italiano has dedicated research facilities, full-time study coordinators, a local College of American Pathologists (CAP)-accredited laboratory and full-service pharmacy. To date, Hospital Italiano has conducted more than 60 trials in 12 different therapy areas with Quintiles – comparable to other Quintiles Prime Sites, and delivered the required subjects for a variety of complex trials for the company.
“Hospital Italiano is founded upon three core tenets: healthcare, education and research,” said Dr. Ventura Simonovich, Clinical Operations Coordinator at Hospital Italiano. “We believe this agreement between Hospital Italiano and Quintiles reinforces our commitment with the community of preserving lives with passion by pursuing excellence in all three areas.”
Key to the success of the Prime Site program is Quintiles’ efforts to harmonize operational processes, drive efficiencies in site start-up and build better relationships with site staff, which, in turn, supports patient recruitment. As increasingly complex clinical trials pose more barriers for effective patient recruitment, Quintiles is combining the power of the digitally-connected patient with the company’s proven scientific and therapeutic expertise to connect the right patients with the right sites at the right time. For instance, the company is developing pre-profiled patient networks and leveraging Electronic Health Record data analytics representing more than 61 million patient lives to provide pre-qualified patient referrals to sites for specific studies. In addition, Quintiles hosts a series of online communities with more than 3.5 million registered users that provide the company with unique insights to enhance its patient recruitment strategies.
“Strong relationships with sites is only the beginning,” said Hecht. “Together, these solutions and services enable patients to better manage their personal health, including opportunities to participate in clinical research, observational studies and disease management programs.”
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Mari Mansfield, Media Relations (mari.mansfield@quintiles.com)
+ 1-919-998-2639 (office) +1-919-259-3298 (mobile)
or
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)
+1-919-998-2789
No comments:
Post a Comment